Financial Daily from THE HINDU group of publications
Monday, January 2, 2006
|
Financial Daily from THE HINDU group of publications Monday, January 2, 2006 |
|
|
|
|
|
News Update as at 17.00 hrs (IST)
Corporate MUMBAI: Orchid Chemicals & Pharmaceuticals Ltd on Monday said that it has received the formal approval from USFDA for its ANDA (Abbreviated New Drug Application) for Cefprozil for Oral Suspension USP, 125 mg /5 ml and 250 mg/5 ml. The current US market size for Cefprozil oral suspension is $120 million, the company informed the Bombay Stock Exchange. The Company is also launching the product in US through its marketing alliance partner, Par Pharmaceuticals (Par). Cefprozil, an anti-biotic, is the generic version of Bristol-Myers Squibb's broad-spectrum Cephalosporin antibiotic Cefzil. The company added that it has already received USFDA approval for Cefprozil Tablets USP 250 mg and 500 mg. It is already commenced its marketing in US in distribution alliance with Par. Together, the tablets and suspension forms have a current brand sale of $237 million. - PTI
Prev: TVS Motors two-wheeler sales up 11 per cent in December Business Line | NUS Index | |
In Focus Dynamic Tirupur Trends in IT - 2005 FDI in retail sector Indian Aviation: Sky is the limit India Inc's bonus bonanza India Inc's overseas acquisition
In Depth Gender Justice Simple Economics Tax Talk
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line
|